(12) **Translation of european patent specification**

(11) **NO/EP 2697199 B1**

NORWAY

(19) NO

(51) Int Cl.

C07D 213/64 (2006.01) A61K 31/4412 (2006.01)
A61K 31/444 (2006.01) A61P 35/00 (2006.01)
C07D 401/12 (2006.01) C07D 405/12 (2006.01)
C07D 409/12 (2006.01) C07D 413/12 (2006.01)
C07D 417/12 (2006.01) C07D 491/08 (2006.01)
C07D 491/107 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2016.10.31
(80)	Date of The European Patent Office Publication of the Granted Patent	2016.06.08
(86)	European Application Nr.	12719529.5
(86)	European Filing Date	2012.04.13
(87)	The European Application's Publication Date	2014.02.19
(30)	Priority	2011.04.13, US, 201161474821 P 2011.06.21, US, 201161499595 P
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:	BA ME
(73)	Proprietor	Epizyme, Inc., 400 Technology Square, 4th Floor, Cambridge, MA 02139, US-USA
(72)	Inventor	KUNTZ, Kevin, Wayne, 8 New Village Road, WoburnMA 01801, US-USA CHESWORTH, Richard, 584 Strawberry Hill Road, ConcordMA 01742, US-USA DUNCAN, Kenneth, William, 132 Roosevelt Avenue, NorwoodMA 02062, US-USA KEILHACK, Heike, 3 Falmouth Street, BelmontMA 02478, US-USA WARHOLIC, Natalie, 81 Strathmore RoadApartment 32, BrightonMA 02135, US-USA KLAUS, Christine, 29 Weyham Road, WeymouthMA 02191, US-USA SEKI, Masashi, Tsukuba Research LaboratoriesEisai Co. Ltd.5-1-3 Tokodai, TsukubashiIbaraki 300-2635, JP-Japan SHIROTORI, Syuji, Tsukuba Research LaboratoriesEisai Co. Ltd.5-1-3 Tokodai, TsukubashiIbaraki 300-2635, JP-Japan KAWANO, Satoshi, Tsukuba Research LaboratoriesEisai Co. Ltd.5-1-3 Tokodai, TsukubashiIbaraki 300-2635, JP-Japan WIGLE, Timothy James Nelson, 111 Marivista Avenue, Waltham, MA 02451, US-USA KNUTSON, Sarah Kathleen, 24 Bay State RoadUnit 22, Cambridge, MA 02138, US-USA
(74)	Agent or Attorney	Tandbergs Patentkontor AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54) Title **ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS**

(56) References Cited:

WO-A1-2011/140324 WO-A1-2011/140325 WO-A1-2012/005805
MIGUEL F. BRAÑA ET AL: "Reaction of N -(2-pyridylmethyl)-3,5-dimethylbenzamide and N -(3-pyridylmethyl)-3,5-dimethylbenzamide N -oxides with acetic anhydride", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 19, no. 6, 1 November 1982 (1982-11-01), pages 1297-1300, XP55030201, ISSN: 0022-152X, DOI: 10.1002/jhet.5570190607

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/

Patentkrav

1. En forbindelse med formel (I) eller et farmasøytisk akseptabelt salt derav:



(I),

hvori

X_1 er N eller CR_{11};
X_2 er N eller CR_{13};
Z er NR_7R_8, OR_7, $S(O)_nR_7$ eller $CR_7R_8R_{14}$, hvori n er 0, 1 eller 2;
hver av R_1, R_5, R_9 og R_{10}, uavhengig av hverandre, er H eller C_1-C_6alkyl eventuelt substituert med én eller flere substituenter valgt fra gruppen bestående av halogen, hydroksyl, COOH, C(O)O-C-$_1$-C_6 alkyl, cyano, C_1-C_6alkoksyl, amino, mono-C_1-C_6alkylamino, di-C_1-C_6alkylamino, C_3-C_8cykloalkyl, C_6-C_{10}aryl, 4 til 12-leddet heterocykloalkyl, og 5- eller 6-leddet heteroaryl;
hver av R_2, R_3 og R_4, uavhengig av hverandre, er -Q_1-T_1, hvori Q_1 er en binding eller C_1-C_3alkyl-linker eventuelt substituert med halogen, cyano, hydroksyl eller C_1-C_6alkoksy, og T_1 er H, halogen, hydroksyl, COOH, cyano, eller R_{S1}, hvori R_{S1} er C_1-C_3alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6alkoksyl, C(O)O-C_1-C_6-alkyl, C_3-C_8cykloalkyl, C_6-C_{10}aryl, amino, mono-C_1-C_6alkylamino, di-C_1-C_6-alkylamino, 4 til 12-leddet heterocykloalkyl eller 5- eller 6-leddet heteroaryl, og R_{S1} eventuelt er substituert med én eller flere substituenter valgt fra gruppen bestående av halogen, hydroksyl, okso, COOH, C(O)O-C-$_1$-C_6alkyl, cyano, C_1-C_6alkoksyl, amino, mono-C_1-C_6alkylamino, di-C_1-C_6alkylamino, C_3-C_8-cykloalkyl, C_6-C_{10} aryl, 4 til 12-leddet heterocykloalkyl, og 5- eller 6-leddet heteroaryl;
R_6 er C_6-C_{10}aryl eller 5- eller 6-leddet heteroaryl, som hver eventuelt er substituert med en eller flere -Q_2-T_2, hvor Q_2 er en binding eller C_1-C_3alkyl-

linker eventuelt substituert med halogen, cyano, hydroksyl eller C_1-C_6alkoksy, og T_2 er H, halogen, cyano, -OR_a, -NR_aR_b. -$(NR_aR_bR_c)^+A^-$, -$C(O)R_a$, -$C(O)OR_a$, -$C(O)NR_aR_b$, -$NR_bC(O)R_a$, -$NR_bC(O)OR_a$, -$S(O)_2R_a$, -$S(O)_2NR_aR_b$ eller R_{S2}, hvori hver av R-$_a$, R_b og R_c er uavhengig av hverandre H eller R_{S3}, A^- er et farmasøytisk akseptabelt anion, og hver av R_{S2} og R_{S3}, uavhengig av hverandre, er C-$_1$-C_6alkyl, C_3-C_8cykloalkyl, C_6-C_{10}aryl, 4- til 12-leddet heterocykloalkyl eller 5- eller 6-leddet heteroaryl, eller R_a og R_b, sammen med N-atomet til hvilket de er bundet, danner en 4- til 12-leddet heterocykloalkylring med 0 eller 1 ytterligere heteroatom, og hver av R_{S2}, R_{S3} og 4- til 12-leddet heterocykloalkyl-ringen dannet av R_a og R_b, eventuelt er substituert med en eller flere -Q_3-T_3, hvor Q_3 er en binding eller C_1-C_3alkyl-linker hver eventuelt substituert med halogen, cyano, hydroksyl eller C_1-C_6alkoksy, og T_3 er valgt fra gruppen bestående av halogen, cyano, C_1-C_6alkyl, C_3-C_8cykloalkyl, C_6-C_{10}aryl, 4- til 12-leddet heterocykloalkyl, en 5- eller 6-leddet heteroaryl, OR_d, $COOR_d$, -$S(O)_2R_d$, -NR_dR_e og -$C(O)NR_dR_e$, hver av R_d og R_e uavhengig av hverandre er H eller C_1-C_6alkyl, eller -Q_3-T_3 er okso; eller til nærliggende -Q_2-T_2, sammen med atomene til hvilke de er bundet, danner en 5- eller 6-leddet ring eventuelt inneholdende 1-4 heteroatomer valgt fra N, O og S og eventuelt substituert med én eller flere substituenter valgt fra gruppen bestående av halogen, hydroksyl, COOH, C(O)O-C_1-C_6alkyl, cyano, C_1-C alkoksyl, amino, mono-C_1-C_6-alkylamino, di-C_1-C_6alkylamino, C_3-C_8cykloalkyl, C_6-C_{10}aryl, 4- til 12-leddet heterocykloalkyl, og 5- eller 6-leddet heteroaryl;

R_7 er -Q_4-T_4, hvori Q_4 er en binding, C_1-C_4alkyl-linker, eller C_2-C_4alkenyl-linker, hver linker er eventuelt substituert med halogen, cyano, hydroksyl eller C_1-C_6-alkoksy, og T_4 er H, halogen, cyano, NR_fR_g, -OR_f, -$C(O)R_f$, -$C(O)OR_f$, -$C(O)NR_fR_g$, -$C(O)NR_fOR_g$, -$NR_fC(O)R_g$, -$S(O)_2R_f$ eller R_{S4}, hvori hver av R_f og Rg er uavhengig av hverandre H eller R_{S5}, hver av R_{S4} og R_{S5} er uavhengig C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_8cykloalkyl, C_6-C_{10}aryl, 4- til 12-leddet heterocykloalkyl eller 5- eller 6-leddet heteroaryl, og hver av R_{S4}og R_{S5} er eventuelt substituert med en eller flere -Q_5-T_5, hvor Q_5 er en binding, C(O), $C(O)NR_k$, $NR_kC(O)$, $S(O)_2$ eller C_1-C_3alkyl-linker, R_k er H eller C_1-C_6alkyl, og T_5 er H, halogen, C_1-C_6alkyl, hydroksyl, cyano, C_1-C_6alkoksyl, amino, mono-C_1-C_6alkylamino, di-C_1-C_6alkylamino, C_3-C_8cykloalkyl, C_6-C_{10}aryl, 4- til 12-leddet heterocykloalkyl, en 5- eller 6-leddet heteroaryl, eller $S(O)_qR_q$ hvori q er 0, 1 eller 2 og Rq er C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_8cykloalkyl, C_6-C_{10}aryl, 4- til 12-leddet heterocykloalkyl eller 5- eller 6-leddet heteroaryl, og T_5 eventuelt er substituert med én eller flere substituenter valgt fra gruppen bestående av halogen, C_1-C_6alkyl, hydroksyl, cyano, C_1-C_6alkoksyl, amino,

mono-C_1-C_6alkylamino, di-C_1-C_6alkylamino, C_3-C_8cykloalkyl, C_6-C_{10}aryl, 4- til 12-leddet heterocykloalkyl, og 5- eller 6-leddet heteroaryl, bortsett fra når T_5 er H, halogen, hydroksyl eller cyano; eller -Q_5-T_5 er okso;
hver av R_8, R_{11}, R_{12} og R_{13}, uavhengig av hverandre, er H, halogen, hydroksyl, COOH, cyano, R_{S6}, OR_{S6}, eller $COOR_{S6}$, hvori R_{S6} er C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_8cykloalkyl, 4- til 12-leddet heterocykloalkyl, amino, mono-C_1-C_6alkylamino eller di-C_1-C_6alkylamino, og R_{S6} eventuelt er substituert med én eller flere substituenter valgt fra gruppen bestående av halogen, hydroksyl, COOH, C(O)O-C_1-C_6alkyl, cyano, C_1-C_6alkoksyl, amino, mono-C_1-C_6-alkylamino, og di-C_1-C_6alkylamino; eller R_7 og R_8, sammen med N-atomet til hvilket de er bundet, danner en 4- til 11-leddet heterocykloalkylring med 0 til 2 ytterligere heteroatomer, eller R_7 og R_8, sammen med C-atomet som de er bundet til, danner C3-C8-cykloalkyl eller en 4- til 11-leddet heterocykloalkylring med 1 til 3 heteroatomer, og hver av de 4- til 11-leddete heterocykloalkylringer eller C_3-C_8cykloalkyl dannet av R_7 og R_8 er eventuelt substituert med en eller flere -Q_6-T_6, hvor Q_6 er en binding, C(O), $C(O)NR_m$, $NR_mC(O)$, $S(O)_2$ eller C_1-C_3-alkyl-linker, R_m er H eller C_1-C_6alkyl, og T_6 er H, halogen, C_1-C_6alkyl, hydroksyl, cyano, C_1-C_6alkoksyl, amino, mono-C_1-C_6alkylamino, di-C_1-C_6-alkylamino, C_3-C_8cykloalkyl, C_6-C_{10}aryl, 4- til 12-leddet heterocykloalkyl, en 5- eller 6-leddet heteroaryl, eller $S(O)_pR_p$ hvori p er 0, 1 eller 2 og R_p er C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_8cykloalkyl, C_6-C_{10}aryl, 4- til 12-leddet heterocykloalkyl eller 5- eller 6-leddet heteroaryl, og T_6 eventuelt er substituert med én eller flere substituenter valgt fra gruppen bestående av halogen, C_1-C_6-alkyl, hydroksyl, cyano, C_1-C_6alkoksyl, amino, mono-C_1-C_6alkylamino, di-C_1-C_6alkylamino, C_3-C_8cykloalkyl, C_6-C_{10}aryl, 4- til 12-leddet heterocykloalkyl, og 5- eller 6-leddet heteroaryl, bortsett fra når T_6 er H, halogen, hydroksyl eller cyano; eller -Q_6-T_6 er okso; og
R_{14} er fraværende, H, eller C-$_1$-C_6alkyl eventuelt substituert med én eller flere substituenter valgt fra gruppen bestående av halogen, hydroksyl, COOH, C(O)O-C_1-C_6alkyl, cyano, C_1-C_6alkoksyl, amino, mono-C_1-C_6alkylamino, di-C_1-C_6-alkylamino, C_3-C_8cykloalkyl, C_6-C_{10}aryl, 4- til 12-leddet heterocykloalkyl, og 5- eller 6-leddet heteroaryl.

2. Forbindelse ifølge krav 1, hvor R_6 er fenyl substituert med en eller flere -Q_2-T_2; eller R_6 er 5- eller 6-leddet heteroaryl inneholdende 1-3 ytterligere heteroatomer valgt fra N, O og S og eventuelt substituert med en eller flere -Q_2-T_2, fortrinnsvis er 5- eller 6-leddet heteroaryl pyridinyl, pyrazolyl, pyrimidinyl, kinolinyl, tetrazolyl, oksazolyl,

isoksazolyl, tiazolyl, isotiazolyl, furyl eller tienyl, som hver eventuelt er substituert med en eller flere -Q_2-T_2.

3. Forbindelse ifølge hvilket som helst av kravene 1-2, hvor T_2 er -NR_aR_b eller -$C(O)NR_aR_b$, hvori hver av R_a og R_b er uavhengig H eller C_1-C_6alkyl, eller R_a og R_b, sammen med N-atomet til hvilket de er bundet, danner en 4- til 12-leddet heterocykloalkylring med 0 eller 1 ytterligere heteroatom, C_1-C_6alkyl, og den 4- til 12-leddete heterocykloalkylringen er eventuelt substituert med en eller flere -Q_3-T_3, og Q_2 er C_1-C_3alkyl-linker eventuelt substituert med halogen eller hydroksyl.

4. Forbindelse ifølge hvilket som helst av kravene 1-3, hvor R_7 er C_1-C_6alkyl, C_3-C_8-cykloalkyl eller 4- til 12-leddet heterosykloalkyl, hver eventuelt substituert med en eller flere -Q_5-T_5; eller R_7 er 4- til 12-leddet heterocykloalkyl eventuelt substituert med en eller flere -Q_5-T_5, fortrinnsvis er R_7 piperidinyl, tetrahydropyran, tetrahydro-2H-tiopyranyl, cyklopentyl eller cykloheksyl, hver eventuelt substituert med en eller flere -Q_5-T_5.

5. Forbindelse ifølge hvilket som helst av kravene 1-4, hvor (i) en eller flere -Q_5-T_5 er okso; eller (ii) T_5 er H, halogen, C_1-C_6alkyl, C_1-C_6alkoksyl, C_3-C_8cykloalkyl, C_6-C_{10}-aryl eller 4- til 12-leddet heterocykloalkyl; eller (iii) når Q_5 er en binding, er T_5 amino, mono-C_1-C_6alkylamino, di-C_1-C_6alkylamino, C_1-C_6alkyl, C_3-C_8cykloalkyl, eller 4- til 12-leddet heterocykloalkyl; eller (iv) når Q_5 er CO, $S(O)_2$ eller NHC(O), er T_5 C_1-C_6-alkyl, C_1-C_6alkoksyl, C_3-C_8cykloalkyl, eller 4- til 12-leddet heterocykloalkyl; eller (v) når Q_5 er C_1-C_3alkyl-linker, er T_5 H, C_6-C_{10}aryl, C_3-C_8cycloalkyl, 4- til 12-leddet heterocyckloalkyl eller $S(O)_qR_q$.

6. Forbindelse ifølge hvilket som helst av kravene 1-5, hvor hver av R_1 og R_{11} er H.

7. Forbindelse ifølge hvilket som helst av kravene 1-6, hvor hver av R_2 og R_4, uavhengig er H eller C_1-C_6alkyl eventuelt substituert med amino, mono-C_1-C_6-alkylamino, di-C_1-C_6alkylamino eller C_6-C_{10}aryl, fortrinnsvis er hver R_2 og R_4 metyl.

8. Forbindelse ifølge hvilket som helst av kravene 1-7, hvor R_{12} er H, metyl, etyl, etenyl eller halogen, R_8 er H, metyl eller etyl, og R_{13} er H eller metyl.

9. Forbindelse ifølge hvilket som helst av kravene 1, hvor forbindelse er av formel (Ie):



(Ie),

fortrinnsvis er forbindelsen av formel (Ig):



(Ig),

hvor R_2, R_4 og R_{12} hver uavhengig er C_{1-6}alkyl.

10. Forbindelse ifølge hvilket som helst av kravene 1 og 9, hvor R_6 er C_6-C_{10}aryl eller 5- eller 6-leddet heteroaryl, hvor hver er eventuelt uavhengig substituert med en eller flere - Q_2-T_2, hvor Q_2 er en binding eller C_1-C_3alkyl-linker, og T_2 er H, halogen, cyano, -OR_a, -NR_aR_b, -$(NR_aR_bR_c)^+A^-$, -$C(O)NR_aR_b$, -$NR_bC(O)R_a$, -$S(O)_2R_a$ eller R_{S2}, hvori hver R_a og R_b, uavhengig er H eller R_{S3}, hver R_{S2} og R_{S3}, uavhengig, er C_1-C_6-alkyl, eller R_a og R_b, sammen med N-atomet til hvilket de er bundet, danner en 4- til 7-leddet heterocycloalkylring som har 0 eller 1 ytterligere heteroatom, og hver R_{S2}, R_{S3}, og den 4- til 7-leddete heterocycloalkylringen dannet av R_a og R_b, er eventuelt, uavhengig substituert med en eller flere -Q_3-T_3, hvor Q_3 er en binding eller C_1-C_3alkyl-linker og T_3 er valgt fra gruppen bestående av halogen, C_1-C_6alkyl, 4- til 7-leddet heterocycloalkyl, OR_d, -$S(O)_2R_d$ og -NR_dR_e, hver R_d og R_e uavhengig er H eller C_1-C_6-alkyl, eller -Q_3-T_3 er okso; eller hver nærliggende -Q_2-T_2, sammen med atomene til

hvilke de er bundet, danner en 5- eller 6-leddet ring eventuelt inneholdende 1-4 heteroatomer valgt fra N, O og S.

11. Forbindelse ifølge hvilket som helst av kravene 1 og 9, hvor forbindelsen er av formel (II):



(II),

hvor Q_2 er en binding eller metyl-linker, T_2 er H, halogen, $-OR_a$, $-NR_aR_b$, $-(NR_aR_bR_c)^+A^-$ eller $-S(O)_2NR_aR_b$, R_7 er piperidinyl, tetrahydropyran, cyclopentyl, eller cykloheksyl, hver eventuelt substituert med én $-Q_5-T_5$ og R_8 er etyl, fortrinnsvis forbindelsen med formel (IIa):



(IIa).

12. Forbindelse ifølge hvilket som helst av kravene 1, 9, og 11, hvor (i) hver R_a og R_b, uavhengig er H eller C_1-C_6alkyl eventuelt substituert med en eller flere $-Q_3-T_3$, (ii) en av R_a og R_b er H, eller (iii) R_a og R_b, sammen med N-atomet til hvilket de er bundet, danner en 4- til 7-leddet heterocycloalkylring som har 0 eller 1 ytterligere hetero-atomer til N-atomet og ringen er eventuelt substituert med en eller flere $-Q_3-T_3$, fortrinnsvis R_a og R_b, sammen med N-atomet til hvilket de er bundet, danner azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oksazolidinyl, isoksazolidinyl, triazolidinyl, tetrahyrofuranyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, piperazinyl,

eller morfolinyl, og ringen er eventuelt substituert med en eller flere $-Q_3-T_3$, og mer foretryukket danner R_a og R_b, sammen med N-atomet til hvilket de er bundet, morfolinyl.

13. Forbindelse ifølge krav 1, hvor forbindelsen er valgt fra

Forbindelse nummer	**Struktur**
1	
2	
3	
4	
5	

Forbindelse nummer	Struktur
6	
7	
8	
9	
10	
11	

Forbindelse nummer	Struktur
12	
13	
14	
15	
16	
17	

Forbindelse nummer	Struktur
18	
19	
20	
21	
22	
23	

Forbindelse nummer	Struktur
24	
25	
26	
27	
28	
29	

Forbindelse nummer	Struktur
30	
31	
32	
35	
36	

Forbindelse nummer	Struktur
37	
38	
39	
40	
41	

Forbindelse nummer	Struktur
42	
43	
44	
45	
46	
47	

Forbindelse nummer	Struktur
48	
49	
50	
51	
52	

Forbindelse nummer	Struktur
53	
54	
55	
56	
57	

Forbindelse nummer	Struktur
58	
59	
60	
61	
62	

Forbindelse nummer	Struktur
63	
64	
65	
66	
67	

Forbindelse nummer	Struktur
68	
69	
70	
71	
72	

Forbindelse nummer	Struktur
73	
74	
75	
76	
77	

Forbindelse nummer	Struktur
78	
79	
80	
81	
82	

Forbindelse nummer	Struktur
83	
84	
85	
86	
87	

Forbindelse nummer	Struktur
88	
89	
90	
91	
92	

Forbindelse nummer	Struktur
93	
94	
95	
96	
97	

Forbindelse nummer	Struktur
98	
99	
100	
101	
102	

Forbindelse nummer	Struktur
103	
104	
105	
106	
107	

Forbindelse nummer	Struktur
108	
109	
110	
111	
112	

Forbindelse nummer	Struktur
113	
114	
115	
116	
117	

Forbindelse nummer	Struktur
118	
119	
120	
121	
122	

Forbindelse nummer	Struktur
123	
124	
125	
126	

Forbindelse nummer	Struktur
127	
128	
129	
130	
131	

Forbindelse nummer	Struktur
132	
133	
134	
135	

Forbindelse nummer	Struktur
136	
137	
138	
139	
140	

Forbindelse nummer	Struktur
141	
142	
143	
144	
145	

Forbindelse nummer	Struktur
146	
147	
148	
149	
150	

Forbindelse nummer	Struktur
151	
152	
153	
154	
155	
156	

Forbindelse nummer	Struktur
158	
159	
160	
161	
162	

Forbindelse nummer	Struktur
163	
164	
165	
166	
167	
168	

Forbindelse nummer	Struktur
169	
170	
171	
172	

Forbindelse nummer	Struktur
173	
174	
175	
176	

Forbindelse nummer	Struktur
177	
178	
179	
180	

Forbindelse nummer	Struktur
181	
182	
183	
184	
185	

Forbindelse nummer	Struktur
186	
187	
188	
189	

Forbindelse nummer	Struktur
190	
191	
192	
193	

Forbindelse nummer	Struktur
194	
195	
196	
197	

Forbindelse nummer	Struktur
198	
199	
200	

og deres farmasøytisk akseptable salter derav, fortrinnsvis er forbindelsen valgt fra

Forbindelse nummer	Struktur
1	

Forbindelse nummer	Struktur
2	
11	
12	
13	
17	
20	

Forbindelse nummer	Struktur
21	
36	
42	
43	
44	

Forbindelse nummer	Struktur
59	
65	
67	
68	
69	

Forbindelse nummer	Struktur
73	
75	
76	
78	
80	

Forbindelse nummer	Struktur
82	
83	
87	
88	
89	

Forbindelse nummer	Struktur
90	
91	
94	
97	
103	

Forbindelse nummer	Struktur
105	
138	
141	

og deres farmasøytisk akseptable salter derav.

14. Forbindelse ifølge krav 1, hvor forbindelsen er



eller et farmasøytisk akseptabelt salt derav.

15. En farmasøytisk sammensetning omfattende en forbindelse ifølge hvilket som helst av kravene 1-14, eller et farmasøytisk akseptabelt salt derav og en farmasøytisk akseptabel bærer.

16. Forbindelse ifølge hvilket som helst av kravene 1-14, for anvendelse i en fremgangsmåte for behandling eller forebygging av kreft.